Prot #VX15-371-101: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Project: Research project

StatusFinished
Effective start/end date4/14/164/14/19

Funding

  • Covance Inc. (Prot #VX15-371-101)
  • Vertex Pharmaceuticals Incorporated (Prot #VX15-371-101)